Is USANA Health Sciences, Inc. overvalued or undervalued?

As of 1 October 2023, USANA Health Sciences, Inc. has moved from fair to attractive in its grade change. The company appears to be undervalued based on its current financial metrics. Key ratios include a price-to-earnings (P/E) ratio of 15.2, a price-to-sales (P/S) ratio of 1.8, and a return on equity (ROE) of 20.5%.
In comparison to its peers, Herbalife Ltd. has a P/E ratio of 18.4, while Nature's Sunshine Products, Inc. stands at a P/E of 14.7. This suggests that USANA is trading at a discount relative to Herbalife, while being slightly higher than Nature's Sunshine, indicating a favorable position in the market. Additionally, USANA's stock has shown resilience, outperforming the Sensex in recent months, further supporting the undervaluation narrative.